Samjin Pharmaceutical announced a strategic investment of 1 billion won ($751,371) in Neurophet, a company specializing in AI solutions for brain disorder imaging, to fight dementia and stroke.

Under the accord, the two companies seek to leverage Samjin’s extensive research resources, infrastructure, and network with Neurophet's brain imaging analysis technology to generate tangible outcomes for future growth ventures.

Neurophet, an enterprise dedicated to developing brain imaging analysis solutions for the entire lifecycle of brain disorders from diagnosis to treatment guidance and therapy, is utilizing its advanced technology in global clinical trials related to the development of Alzheimer's disease drug and treatment technology.

Moving forward, both companies plan to engage in substantive discussions on collaboration, with a focus on driving product commercialization.

"We are delighted to welcome Neurophet, which possesses exceptional technology in the rapidly growing field of AI, particularly in brain imaging analysis, as a strategic partner,” Samjin CEO Choi Yong-ju said. “We look forward to actively supporting and continuing a long-term cooperative relationship starting with this investment."

Neurophet CEO Been Jun-kil also said, "We expect that both companies will make every effort to achieve business success in the field of brain disorders such as dementia and stroke.”